M. Goto

Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.

S. Masuda, K. Tanaka, K. Inui, 2005, Transplantation proceedings.

C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.

S. Uemoto, S. Masuda, H. Saito, 2002, Pharmacogenetics.

Tacrolimus Therapy According to Mucosal MDR1 Levels in Small‐bowel Transplant Recipients

S. Uemoto, S. Masuda, K. Inui, 2004, Clinical pharmacology and therapeutics.

Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients

O. Ogawa, S. Masuda, N. Ito, 2004, Journal of Human Genetics.

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.

S. Masuda, M. Okuda, K. Inui, 2004, Pharmacogenetics.

Enhanced expression of enterocyte P‐glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation

S. Uemoto, S. Masuda, H. Saito, 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2.

S. Masuda, H. Saito, K. Inui, 2003, Biochemical pharmacology.

Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living‐donor liver transplant patients

S. Masuda, M. Uesugi, K. Inui, 2006, Clinical pharmacology and therapeutics.

Gene expression levels and immunolocalization of organic ion transporters in the human kidney.

Hideyuki Saito, Osamu Ogawa, Satohiro Masuda, 2002, Journal of the American Society of Nephrology : JASN.

Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living‐donor liver transplant recipients

S. Uemoto, S. Masuda, M. Fukudo, 2006, Clinical pharmacology and therapeutics.

Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile.

S. Uemoto, S. Masuda, K. Inui, 2008, Drug metabolism and pharmacokinetics.

Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation

S. Uemoto, S. Masuda, K. Inui, 2008, Journal of Pharmacology and Experimental Therapeutics.

Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum.

S. Masuda, M. Okuda, K. Inui, 2005, Biochemical pharmacology.